Literature DB >> 3372687

Effects of acute high dose and chronic low dose estrogen on plasma somatomedin-C and growth in patients with Turner's syndrome.

K C Copeland1.   

Abstract

Previously reported data with regard to the effects of estrogen on plasma somatomedin-C (Sm-C) concentrations are contradictory. This study was designed to evaluate, in the same subjects with Turner's syndrome, the effects of both acute high dose and chronic low dose estrogen treatment on plasma Sm-C concentrations. Eight girls with Turner's syndrome, aged 10 8/12 to 14 9/12 yr, were admitted to the Clinical Research Center for 3 days. Each received an iv infusion of conjugated estrogens (1.25 or 2.5 mg) in 12 h. Plasma Sm-C and serum GH and estrone levels were measured before, during, and after the infusion. The mean serum concentrations in the girls who received 1.25 mg conjugated estrogen increased from less than 222 pmol/L to 1905 +/- 240 (+/- SE), 825 +/- 166, and 296 +/- 74 pmol/L immediately after, 12 h after, and 24 h after completion of the infusion, respectively. Serum GH concentrations were undetectable (less than 1 microgram/L) before, during, and after the infusion. The mean plasma Sm-C concentrations decreased significantly (P = 0.02) after the infusion was terminated, falling from a mean basal value of 1.3 +/- 0.2 (+/- SE) to a nadir of 0.6 +/- 0.1 U/mL 12 h after completion of the infusion. The same girls then were treated with low dose (5 micrograms ethinyl estradiol) estrogen therapy for 9-14 months. Seven of the eight girls had an increase in growth rate. The mean growth rate increased from 2.0 +/- 0.5 to 5.4 +/- 0.8 and 3.8 +/- 0.4 cm/yr from 3 to 6 (P less than 0.05) and from 9 to 14 months of treatment, respectively. Individual variability was great, however, and two of the eight girls never grew at a rate faster than 4.0 cm/yr during therapy. No consistent alteration in bone age relative to chronological age was found, and the growth response was not predicted by the bone age at the beginning of treatment. Mean plasma Sm-C concentrations did not change. These studies demonstrated a growth spurt in girls with Turner's syndrome during chronic low dose estrogen therapy, which was not associated with any change in plasma Sm-C concentrations. Acute high dose iv estrogen infusion resulted in a significant decline in plasma Sm-C concentrations. These results support the concept that in girls with Turner's syndrome the plasma Sm-C response to estrogen is influenced by multiple, as yet undefined, factors.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3372687     DOI: 10.1210/jcem-66-6-1278

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  4 in total

Review 1.  Interactive regulation of postmenopausal growth hormone insulin-like growth factor axis by estrogen and growth hormone-releasing peptide-2.

Authors:  J D Veldhuis; W S Evans; C Y Bowers; S Anderson
Journal:  Endocrine       Date:  2001-02       Impact factor: 3.633

Review 2.  Regulation of insulin-like growth factors by antiestrogen.

Authors:  R Winston; P C Kao; D T Kiang
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

3.  Tamoxifen modulation of etoposide cytotoxicity involves inhibition of protein kinase C activity and insulin-like growth factor II expression in brain tumor cells.

Authors:  Cheppail Ramachandran; Ziad Khatib; Athena Petkarou; John Fort; Hugo B Fonseca; Steven J Melnick; Enrique Escalon
Journal:  J Neurooncol       Date:  2004 Mar-Apr       Impact factor: 4.130

4.  Effect of two-4-hydroxyandrostenedione doses on serum insulin-like growth factor I levels in advanced breast cancer.

Authors:  L Ferrari; N Zilembo; E Bajetta; R Buzzoni; C Noberasco; A Martinetti; L Celio; E Galante; S Orefice; A M Cerrotta
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.